SAR 366234

Drug Profile

SAR 366234

Alternative Names: SAR366234

Latest Information Update: 08 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi
  • Class Eye disorder therapies
  • Mechanism of Action Prostaglandin E EP2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ocular hypertension

Most Recent Events

  • 28 Oct 2016 Discontinued - Phase-I for Ocular hypertension in USA (Ophthalmic)
  • 01 Apr 2016 Sanofi completes a phase I trial in Ocular hypertension in USA (Ophthalmic) (NCT02531152)
  • 01 Aug 2015 Phase-I clinical trials in Ocular hypertension in USA (Ophthalmic) (NCT02531152)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top